Member Info for David1951c

With a lot happening there could be news at any time. Bought back in with 350k shares but shown on LSE as a sell.

Agree AT and team have been impressive in their actions and focus. I have looked at the investor meet presentations more than once and they come through as believable and trustworthy too. I would have thought they could buy more shares to increase their holdings and show their confidence in the future. As much as anything we need a clearer insight on revenue. We know annual costs are £3.5m but not when break even is expected.

With a MCap of £3m it is unlikely institutional investors would come in unless a VCT takes an interest. The company have a lot to do to convince investors after the shockingly discounted fund raise last year (78% discount). With fixed expense base of only £3.5m it is really peanuts for a company with so much potential. Surely there is a cornerstone investor who would put in £2m or more to get them through 2024.

Yes actual revenue numbers and a clear timescale to reach break even are critical. Some are worried that we will be hit with another discounted placement. Director purchases would show more confidence that they believe in what they are achieving.

I used to be invested here but sold out last year due to falling SP and lack of clear path and timescales to break even.

Current SP makes it tempting but in spite of great progress on commercial side, future revenue is unclear as is the profit margin. I will wait for next results in May as AIM is appalling for companies like this and further drift in SP likely with no news. A trading update would help with some numbers.

The issue for most investors is having no idea of the revenue from existing and new customers / hospitals to determine when the company will break even ending the risk of another diluting and heavily discounted fund raise.

Potential is good and I have bought shares but will not increase my holding when so little is known about the finances.

Re 75% required to delist, according to website major shareholders including directors have less than 40% so it would appear a major barrier.

OBI have partners in USA for P3. "HCA Healthcare is partnering with Ondine in the United States to conduct a US Phase 3 clinical trial with the ultimate goal of obtaining FDA approval to bring Ondine's nasal photodisinfection into the US market. HCA Healthcare operates 184 hospitals and over 2,000 sites of care across the United States, making it the largest healthcare system in the US."

So costs may not be huge as HCA have many patients to participate.

Totally agree that there is so little information on pricing or volumes to make an informed decision. Use is broadening but if the margins are thin to attract business, the break even point may be some way off.

Do the company have to obtain 75% of the votes to proceed? The small shareholders need to ensure that they vote against but is that so easy when via nominees e.g. HL or AJB?

Steriwave has great potential and the fact it is approved in numerous markets should mean usage will increase significantly. What is unclear is the pricing and what volumes are needed to reach break even point. The trial costs in USA are unclear too but OBI are working with a hospital group that should help defray the costs. Finding a commercial partner to increase volumes may be another way forward.

Last fund raise was not at a discount and with such a low Mcap the prospects are significant. Anyway worth a punt so bought 50,000 shares for 9.1p (about last placing price) although shown as a sell on here.

Not sure what to make of this as MCap of £2.5m is so low there could be huge gains if the funding side became clearer. The last placing was at such a large discount, many are wary. Surprised there have been no director share purchases that would show their confidence more than words. Time will tell but as shares can be bought at 0.52p this must be a high risk and reward play.

I was invested here for some years and sold out in 2022. On watch list and what stops me going back in is lack of info on when revenue from gold sales will commence. The raised amount won't last long and could another raise be needed in six months? Use of funds also refers to acquisition which must be pie in the sky.

Those willing to hold delisted shares will be able to buy them very cheaply today and might make huge profit in time. Probably directors, managers, friends and large shareholders have a huge advantage. Small shareholders are treated very badly and have so little protection. AIM is a disgrace. Worry is this may set a trend.

Important issue is that it may not be possible to hold delisted shares in and ISA? SIPP may depend on provider?

In my view Opti is not much different than a number of the companies that TW criticises for lack of progress, lack of income and likely discounted future fund raises. This may be one of his largest holdings but one of his least successful holds probably.

I have been following this for more than a year and made a first investment today of 45k shares (shown as a sell on here). I will buy more if I could understand the financial side and likely revenue from the NHS and other hospitals adopting Steriwave. Research continues.

Cyan claim to be a world leader in narrowband radio frequency (RF) mesh networks but is this a fact or just blowing their own trumpet? Also, order numbers are impressive but it is unclear how many were completed in H2 after a big rise in H1. They also say that revenue expectations will be met.

I am invested here but reluctant to add until the actual progress is clearer. There are numerous posts on here about lack of news which is a worry as no news is generally bad news on small caps.

People are wary of AIM. Just look what is happening with companies unable to raise additional funds which was not such a huge issue two years ago. Latest failures like Bidstack and Loop up leaving AIM with massive drop in SPs are a material hit for small cap investors. I have to be careful even though I have accumulated 3m shares in last three months. As a small investor that is quite a lot for me.

The fund raise last July was at a 78% discount and hurt LTHs and other then recent investors as the SP had been even higher. I have watched the last Investor Meet recording twice and re-read the RNSs of the last year multiple times. I have looked at their website. I think the Market Cap (SP) is ridiculously low and there is great potential but until the income stream rises there is always a risk that needs to be continuously reassessed.

I feel more confident after the Unilever announcement but that hardly moved the SP at all. Why was that??

Apta could do with a cornerstone investor to come in and provide the foundation to enable the company to progress further and faster than limited funds allow.

This will be a good opportunity to get to hear about the technical side. The issue for investors is more around finances and funding to get to break even. A few more director share purchases at the current low price would help raise confidence.

Perhaps Unilever would provide a loan to keep the company on track with reaching that point. I am tempted to buy more but wary of over committing.

LTB - I understand the confidentiality of some deals but the announcement does not allay concerns about funding even if there is enough for the next 12 months. The SP should now be higher but the BoD are still building up the company and investor confidence after the shock of last year's low placing. I think this could be a winner and bought another 250k shares shown as a sell on LSE.

There is no information or indications of the income from the partnership and doubts remain about future funding. I doubt Unilever would enter into a partnership with due diligence including finances but there is no doubt a finite cash runway until a decent income stream is reached. It is crazy that company has a market cap of only £4m and this is another indication of the failure of LSE and AIM in particular to finance small company development. Loop up cancelled their listing today which also shows AIM is a poor choice of listing.

It would be great for Apta to find a cornerstone investor to help finance the next stages of development and perhaps Unilever will provide capital - a few million is chicken feed for them.